Fig. 8: Amplified antitumour effects of NIL-IM-Lip + L and PD−1 mAb cotreatment in hot tumours (B16F10 model) and cold tumours (CT26 model). | Nature Communications

Fig. 8: Amplified antitumour effects of NIL-IM-Lip + L and PD−1 mAb cotreatment in hot tumours (B16F10 model) and cold tumours (CT26 model).

From: Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling

Fig. 8: Amplified antitumour effects of NIL-IM-Lip + L and PD−1 mAb cotreatment in hot tumours (B16F10 model) and cold tumours (CT26 model).The alt text for this image may have been generated using AI.

Mice were euthanized when the tumour volumes reached ~2000 mm3. a Schedule of the NIL-IM-Lip+L combined with PD-1 mAb experiment in B16F10 tumour-bearing C57BL/6 mice. b Tumour volume curves of different formulations (n  =  5 biologically independent animals per group). c Photographs of tumours after 16 days of treatment (n  =  5 biologically independent animals per group). d Individual tumour volume curves after treatment with different formulations (n  =  5 biologically independent animals per group). e Tumour weights in different formulation-treated groups (n  =  5 biologically independent animals per group). f, g Flow cytometric analysis of the intratumoural CTLs, CD4+ T cells and CD8+ T cells, NK cells and Treg cells (n  =  3 biologically independent experiments per group). h, i Flow cytometric analysis of the infiltration of DCs, CD4+ T cells, CD8+ T cells, NK cells and Treg cells in the LNs (n  =  3 biologically independent experiments per group). j Schedule of the NIL-IM-Lip+L combined with PD-1 mAb antitumour experiment in CT26 tumour-bearing BALB/c mice. k Tumour volume curves of different formulations (n  =  5 biologically independent animals per group). l, Photographs of tumours after 16 days of treatment (n  =  5 biologically independent animals per group). m Tumour weights in different formulation-treated groups (n  =  5 biologically independent animals per group). n Individual tumour volume curves after treatment with different formulations (n  =  5 biologically independent animals per group). o, q Flow cytometric analysis of the intratumoural CTLs, CD4+ T cells, CD8+ T cells q, NK cells and Treg cells (n  =  3 biologically independent experiments per group). p, r Flow cytometric analysis of the infiltration of DCs, CD4+ T cells and CD8+ T cells (r), NK cells and Treg cells in the LNs (n  =  3 biologically independent experiments per group). Data are presented as mean values ± SD. Statistical significances were calculated by one-way analysis of variance with Tukey’s post hoc test. *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file. PD-1: PD-1 mAb; NIL-IM-Lip+PD-1 + L: the combination the NIL-IM-Lip+L and PD-1 mAb.

Back to article page